Solid Biosciences Inc. Share Price

Solid Biosciences Inc. Share Price

NASDAQ: SLDB | Small Cap
$6.39
-$0.08 (-1.31%) Last updated on 30 Oct, 2026 | 01:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Solid Biosciences Inc. Stock Performance

Open
$6.55
Prev. Close
$6.47
Circuit Range
N/A
Day Range
$6.27 - $6.65
Year Range
$3.79 - $11.45
Volume
61,281
Average Traded
$6.45

Solid Biosciences Inc. Share Price Today

As of 30 October 2026, Solid Biosciences Inc.'s share price is $6.39. The stock opened at $6.55, compared to its previous close of $6.47. During today's trading session, Solid Biosciences Inc.'s share price traded between $6.27 and $6.65, with an average price of $6.46. Over the past 52 weeks, the stock has recorded a high of $11.45 and a low of $3.79. In terms of performance, Solid Biosciences Inc.'s share price has declined by 11.86% over the last six months and is up 18.99% on a year-on-year basis.

Solid Biosciences Inc. Share Price Chart

Line chart of the Solid Biosciences Inc. price trend over the selected period. The price fell overall, ranging from 6.27 to 6.64, ending at 6.40.
$6.27$6.65
L
Show Current Price
H

Solid Biosciences Inc. Stock Fundamentals & Key Indicators

Market Cap
$559.15M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-1.93
Revenue (TTM)
$0.00
Return On Equity (TTM)
-55.36%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-19.70%

Solid Biosciences Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$45.78-$49.79-$56.74-$54.80
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-8.76%-13.96%3.42%

Solid Biosciences Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$8.09$0.00$0.00$0.00
Net Profit-$85.98-$96.02-$124.70-$174.33
Net Profit Margin-1062.79%N/AN/AN/A
Income ChangeN/A-11.68%-29.87%-39.80%

About Solid Biosciences Inc.

Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.

Solid Biosciences Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$7.15
$6.41
-11.29%
Sep 2026
$9.38
$7.22
-28.73%
Aug 2026
$8.05
$10.13
+25.92%
Jul 2026
$10.02
$8.04
-19.39%
Jun 2026
$7.25
$9.98
+35.87%
May 2026
$7.29
$7.34
+1.31%
Apr 2026
$7.31
$7.25
+0.83%
Mar 2026
$6.07
$7.19
+15.59%
Feb 2026
$6.40
$6.22
-3.79%
Jan 2026
$5.58
$6.46
+14.22%
Dec 2025
$5.26
$5.66
+4.33%
Nov 2025
$5.34
$5.42
+1.02%

SLDB Share Price FAQs